Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older, of any gender.
- People who are willing to take part in the study and have signed a written consent form agreeing to participate.
- People who either have a strong medical suspicion of lung cancer (a specific type called non-small cell lung cancer) that may or may not be able to be removed by surgery, or who have already had this type of lung cancer confirmed through a tissue test.
- People who are covered by, or entitled to benefits from, a social security system.
Who may not be able to join:
- People who are in an emergency situation, people who are under a legal protection order (such as guardianship or court-appointed protection), or people who are not able to give their own informed consent to participate.
- People who would be unable to attend the required medical check-ins during the study, whether due to where they live, their personal circumstances, or their mental or emotional wellbeing.
- People who have previously had a transplant of a solid organ (such as a kidney, liver, or heart) or a bone marrow/stem cell transplant.
- People who are pregnant or currently breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0491223824
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
"The primary objective is to assess the association between the immune signature in peripheral blood and the efficacy of immunotherapies in patients with advanced-stage NSCLC
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.